Pfizer, Eli Lilly Post Fourth-Quarter Results; Both Score High on Our Valuentum Dividend Cushion
publication date: Jan 31, 2012
Pfizer and Eli Lilly posted fourth-quarter results with each showing the impact of the industry's "patent cliff." Pfizer has lost exclusivity of Lipitor, while Eli Lilly is now facing competition for its blockbuster drug Zyprexa. Though their respective outlooks remain challenged, the safety of their current dividends remains excellent based on their respective Valuentum Dividend Cushion scores.
To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.